InvestorsHub Logo
Followers 19
Posts 615
Boards Moderated 0
Alias Born 11/19/2004

Re: None

Friday, 12/02/2016 2:47:38 AM

Friday, December 02, 2016 2:47:38 AM

Post# of 1137
News from Nov 29:

miRagen Therapeutics Expands Executive Leadership Team

---------------------

Paul Rubin, M.D. Joins as Executive Vice President of Research and Development

BOULDER, CO., November 29, 2016 – miRagen Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of innovative microRNA (miRNA)-targeting therapies in disease areas of high unmet medical need, today announced the appointment of Paul Rubin, M.D. to the position of Executive Vice President of Research and Development. Dr. Rubin is a seasoned biopharmaceutical executive with expertise across a range of drug modalities and therapeutic areas. He has been responsible for clinical development programs, which led to regulatory approval of several products during his career with several pharmaceutical and biotechnology companies.

“Paul brings an impressive breadth and depth of experience in drug discovery and development to our team.” said William S. Marshall, Ph.D., President and Chief Executive Officer of miRagen. “I’m excited to welcome him to the miRagen team and look forward to working together to advance our product candidate portfolio.”

“I welcome the opportunity to contribute to the advancement of miRagen’s platform of RNA-based therapeutics”, said Dr. Rubin. “I am particularly excited to join the team presently managing miRagen’s two lead candidates, MRG-106 for the treatment of certain cancers, and MRG-201 for the treatment of pathological fibrosis as they continue to advance these products in clinical trials.”

Prior to joining miRagen, Dr. Rubin held various roles at Xoma Corporation from June 2011 to November 2016, most recently serving as its Chief Medical Officer, and Senior Vice President of Research and Development. Prior to joining Xoma Corporation, Dr. Rubin was the Chief Medical Officer at Funxional Therapeutics Ltd. from February 2011 to June 2011, the Chief Executive Officer of Resolvyx Pharmaceuticals, Inc. from 2007 to 2009 and the President and Chief Executive Officer of Critical Therapeutics, Inc. from 2002 to 2007.

From 1996 to 2002, Dr. Rubin held various roles with Sepracor, Inc., where he served as Senior Vice President, Development, and later as Executive Vice President, Research & Development. While at Sepracor he led the development of Sepracor’s internally developed approved products including Xopenex ® , Lunesta ® , Xopenex HFA ® and Brovana ® .

From 1993 to 1996, Paul held senior level positions at Glaxo-Wellcome Pharmaceuticals, including Vice President of Worldwide Clinical Pharmacology and Early Clinical Development. From 1987 to 1993, Dr. Rubin held various roles with Abbott Laboratories, including as Vice President, Immunology and Endocrinology, where he successfully advanced zileuton, the first 5-lipoxygenase inhibitor, from discovery to approval for the treatment of asthma.

Dr. Rubin received a B.A. from Occidental College and an M.D. from Rush Medical College. He completed his training in internal medicine at the University of Wisconsin.